Abstract

The phase III ADAURA trial showed a significant disease-free survival (DFS) benefit for adjuvant osimertinib versus placebo in resected stage IB-IIIA EGFR mutated non-small cell lung cancer (NSCLC). The aim of this analysis was to estimate EGFR mutation prevalence, treatment patterns and long-term outcomes in early stage (IB-IIIA) resected NSCLC patients in a real-world setting.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.